Form 4: ADIAL PHARMACEUTICALS Director Kevin Schuyler Granted 28,000 Stock Options

ADIAL Pharmaceuticals, Inc. director Kevin Schuyler was granted 28,000 stock options with an exercise price of $0.688, vesting monthly over 36 months.

Summary

• Kevin Schuyler, a Director of ADIAL PHARMACEUTICALS, INC. (ADIL), was granted 28,000 stock options.
• The transaction date for this grant was May 29, 2025.
• The exercise price for these stock options is $0.688 per share.
• The options will vest pro rata on a monthly basis over a period of 36 months, commencing from May 29, 2025.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Kevin Schuyler beneficially owns 28,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, as it aligns management's interests with shareholders. It's a routine compensation item and not indicative of significant operational or financial changes.

Positives

• The grant of stock options to Director Kevin Schuyler aligns his interests with those of the shareholders, as the value of the options increases with the company's stock price.
• This is a standard form of compensation that can incentivize long-term commitment and performance from the director.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although the amount is relatively small.

Risks

• The value of the stock options is dependent on the future performance of ADIAL PHARMACEUTICALS' stock, which carries inherent market risks.
• If the stock price does not exceed the exercise price of $0.688, the options may expire worthless.

Future Outlook

The stock options granted to Director Kevin Schuyler will vest monthly over the next 36 months, indicating a future increase in his beneficial ownership of common stock if the options are exercised.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the grant of stock options as part of director compensation, which is a common practice across various industries, including the pharmaceutical sector, to incentivize leadership.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice in publicly traded companies, aligning director incentives with shareholder value creation.
• The vesting schedule over 36 months is typical for long-term incentive plans, comparable to those seen in other biotech and pharmaceutical companies aiming for sustained performance.

Related Party Transactions

• The grant of stock options to Kevin Schuyler, a Director of ADIAL PHARMACEUTICALS, INC., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefit from aligned director incentives.
• Director (Kevin Schuyler): Receives equity-based compensation, aligning personal financial interests with company performance.

Next Steps

• The stock options will continue to vest pro rata on a monthly basis over the next 36 months.

Key Dates

Keywords

ADIAL Pharmaceuticals, ADIL, Form 4, SEC filing, stock options, director compensation, insider transaction, beneficial ownership, equity compensation, vesting schedule